6575-18-4

Upstream product

• 99-30-9 4-nitro-2,6-dichloroaniline 
• 2112-17-6 2,6-dichloro-4-nitrobenzonitrile 
• 1940-29-0 4-bromo-3,5-dichloroaniline 

Downstream Products

• 1533434-62-6 (Z)-methyl N'-cyano-N-(3,5-dichloro-4-cyanophenyl)carbamimidothioate 
• 1533423-94-7 4-(5-amino-1H-[1,2,4]triazol-3-ylamino)-2,6-dichlorobenzonitrile 
• 1533424-76-8 2,6-dichloro-4-isothiocyanatobenzonitrile 

Relevant academic research and scientific papers

ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS

The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human.

TRIAZOLE COMPOUNDS AS ANTIVIRALS

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

ANTIVIRAL COMPOUNDS

The present invention discloses compounds of Formula (I): wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

ANTIVIRAL COMPOUNDS

The present invention discloses compounds of Formula (I): wherein the variables in Formula (I) are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula (I) in the prevention or treatment of HCV infection.